Today: 9 April 2026
Rivian stock slips after 19,641-vehicle recall as jobs data and VW tie-up hit tape
9 January 2026
2 mins read

Rivian stock slips after 19,641-vehicle recall as jobs data and VW tie-up hit tape

New York, January 9, 2026, 09:31 ET — Regular session

  • Rivian shares fell about 0.9% early Friday after U.S. regulators disclosed a recall tied to a rear suspension part.
  • Piper Sandler lifted its price target, while an SEC filing showed CEO R.J. Scaringe sold shares under a pre-set plan.
  • Investors also weighed a softer December U.S. jobs report and fresh headlines tied to Rivian’s Volkswagen software work.

Rivian Automotive, Inc. shares were down about 0.9% at $19.89 in early trade on Friday after U.S. safety regulators said the company is recalling 19,641 electric vehicles over an improperly reassembled rear toe link, a part of the rear suspension. The National Highway Traffic Safety Administration said Rivian will replace the rear toe-link bolts free of charge and cited one crash with minor injuries. reuters.com

The recall lands on a company still trying to keep a lid on costs while it pushes volume. In 2025, Rivian produced 42,284 vehicles and delivered 42,247, so even a “service-only” issue can get attention when the stock is trading like every dollar matters.

Markets were also chewing on the U.S. jobs report. Nonfarm payrolls — the government’s broad count of jobs outside farming — rose 50,000 in December, below the 60,000 economists expected in a Reuters poll, and the unemployment rate eased to 4.4%. Peter Cardillo, chief market economist at Spartan Capital Securities, called it “not too hot, not too cold.” reuters.com

Rivian also showed up in partner headlines. Volkswagen said it plans to use Qualcomm chips in a new software platform it is developing with Rivian, and tied a $1 billion investment to hitting technical milestones this year.

On the Street, Piper Sandler raised its price target on Rivian to $20 from $14 and kept a Neutral rating. The firm flagged affordability as a drag in 2026 and said it expects North American sales to fall 1.2% this year. TipRanks

The recall covers certain 2022 through 2025 R1S SUVs and R1T pickups that previously had rear suspension service between April 1, 2022 and March 10, 2025, Car and Driver reported, citing NHTSA documents. The toe link can separate in some cases, raising crash risk, and Rivian plans to start owner notifications on Feb. 24, when related VINs become searchable. Car and Driver

A regulatory filing also showed CEO Robert J. Scaringe sold 17,450 shares on Jan. 6 at prices ranging from $19.07 to $20.02. The Form 4 said the sales were made under a 10b5-1 plan, a pre-arranged trading program used by insiders. Securities and Exchange Commission

Rivian lagged some peers early on Friday: Tesla rose about 1%, Lucid gained about 2.3% and Ford was up about 4.8%. Rivian is hovering around the $20 level and sits below a 52-week high of $22.67 and above a low of $10.37, according to Markets Insider data. markets.businessinsider.com

But the repair count and timing still sit in a grey area. If more cases surface or fixes bottleneck at service centers, investors could start penciling in higher warranty costs — and that tends to hit growth names fast.

Next up: investors will watch for any further disclosure on recall progress as Feb. 24 nears, and for Rivian’s fourth-quarter and full-year results on Feb. 12 after the market close, when the company plans a 5 p.m. ET webcast. Securities and Exchange Commission

Stock Market Today

  • Ultragenyx Pharmaceutical Shares Surge 8.1% Weekly Amid Valuation Debate
    April 9, 2026, 2:08 AM EDT. Ultragenyx Pharmaceutical (RARE) shares rose 8.1% last week to $23.15 amid mixed performance, down 1.9% year-to-date and 31.7% over 12 months. The biotech specializes in rare disease treatments, a sector sensitive to clinical trial and regulatory updates. Despite recent gains, the company's long-term returns remain negative. A discounted cash flow (DCF) analysis values Ultragenyx at about $257.43 per share, suggesting it is 91% undervalued based on future free cash flow projections turning positive by 2026. However, actual cash flow remains negative at $501.5 million last year. Investors must weigh DCF optimism against market risks and sector volatility. Ultragenyx scores 4 out of 6 in valuation, indicating some appeal but highlighting areas needing scrutiny.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 09.04.2026

9 April 2026
LIVEMarkets rolling coverageStarted: April 9, 2026, 12:00 AM EDTUpdated: April 9, 2026, 2:16 AM EDT Ultragenyx Pharmaceutical Shares Surge 8.1% Weekly Amid Valuation Debate April 9, 2026, 2:08 AM EDT. Ultragenyx Pharmaceutical (RARE) shares rose 8.1% last week to $23.15 amid mixed performance, down 1.9% year-to-date and 31.7% over 12 months. The biotech specializes in rare disease treatments, a sector sensitive to clinical trial and regulatory updates. Despite recent gains, the company's long-term returns remain negative. A discounted cash flow (DCF) analysis values Ultragenyx at about $257.43 per share, suggesting it is 91% undervalued based on future free cash flow
Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
Broadcom stock slides after $4.5 billion bond pricing; Wall Street looks past the noise
Previous Story

Broadcom stock slides after $4.5 billion bond pricing; Wall Street looks past the noise

Apple stock today: AAPL slips as Apple Card shifts to JPMorgan with earnings in view
Next Story

Apple stock today: AAPL slips as Apple Card shifts to JPMorgan with earnings in view

Go toTop